Study guide

7.4 Infective Endocarditis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

7.4 Infective Endocarditis

Key Takeaways Explain This Topic AI

Definite endocarditis requires two major modified Duke criteria, or one major plus three minor, or five minor criteria.

Streptococcus gallolyticus (formerly Streptococcus bovis) endocarditis mandates colonoscopy because of its strong association with colorectal neoplasia.

Surgery is indicated for heart failure from valve destruction, uncontrolled infection or abscess, and recurrent embolism with a vegetation larger than 10 mm.

Last updated: September 2026

  • 5. Infective Endocarditis (IE)
  • Microbiology

Staphylococcus aureus (~35–40%): Most common cause overall in high-income nations. Characterized by acute, rapidly destructive presentations on previously normal native valves. Predominant organism in intravenous drug users (IVDU), classically affecting the tricuspid valve and presenting with septic pulmonary infarcts, cavitation, and pleuritic chest pain without peripheral stigmata.

Viridans Group Streptococci ( S. sanguinis , S. mitis , S. mutans ) (~20–25%): Cause subacute native valve endocarditis on abnormal or diseased valves (rheumatic, BAV, prolapse). Typically follow dental procedures or poor oral hygiene.

Streptococcus gallolyticus ( formerly S. bovis ): Strongly associated with underlying colorectal carcinoma or premalignant villous adenomas. Isolation mandates immediate full colonoscopy .

Enterococcus faecalis / faecium: Associated with older men following transurethral resection of the prostate (TURP), cystoscopy, or gastrointestinal instrumentation.

Coagulase-Negative Staphylococci ( S. epidermidis ): Major cause of early prosthetic valve endocarditis (PVE within 12 months of valve surgery) and central line infections.

HACEK Group: Fastidious gram-negative bacilli ( Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella ). Indolent presentation; often culture-negative on routine standard media, requiring extended incubation.

Culture-Negative IE: Coxiella burnetii (Q fever; diagnose via Phase I IgG serology), Bartonella henselae/quintana , Chlamydia , Brucella , Tropheryma whipplei . Non-bacterial thrombotic endocarditis (Marantic) occurs in advanced malignancy; Libman-Sacks endocarditis occurs in systemic lupus erythematosus.

Modified Duke Criteria for Diagnosis

Definitive diagnosis requires: 2 Major criteria , OR 1 Major + 3 Minor criteria , OR 5 Minor criteria .

Major Criteria Minor Criteria

1. Positive Blood Cultures for IE: ; • Typical microorganisms from 2 separate blood cultures ( S. aureus , Viridans streptococci, S. gallolyticus , Enterococci, HACEK), OR; • Persistently positive cultures: drawn >12 hours apart, or all of 3 (or majority of >=4) cultures positive, OR; • Single positive culture for Coxiella burnetii (or Phase I IgG antibody titre >1:800) 1. Predisposition: Pre-existing high-risk cardiac lesion (prosthetic valve, prior IE, cyanotic congenital disease) or intravenous drug use

2. Evidence of Endocardial Involvement: ; • Echocardiography positive for IE: oscillating intracardiac mass (vegetation) on valve or supporting structures, perivalvular abscess, pseudoaneurysm, or new partial dehiscence of prosthetic valve, OR; • New valvular regurgitation (worsening or changing of pre-existing murmur not sufficient) 2. Fever: Core temperature >= 38.0°C

3. Vascular Phenomena: Major arterial emboli, septic pulmonary infarcts, mycotic aneurysms, intracranial haemorrhage, conjunctival haemorrhages, and Janeway lesions (non-tender, erythematous macules on palms/soles from septic microemboli)

4. Immunologic Phenomena: Glomerulonephritis, Osler nodes (painful, tender violaceous nodules on the pads of fingers/toes due to immune complex deposition), Roth spots (oval retinal haemorrhages with pale, white centres), and positive serum rheumatoid factor

5. Microbiological Evidence: Positive blood culture not meeting major criteria, or serological evidence of active infection with compatible organism

Antibiotic Protocols & Indications for Urgent Surgery

Blood Culture Sampling: Draw 3 sets of blood cultures from separate venepuncture sites with at least 30 minutes between draws before initiating antibiotics (unless patient is in septic shock).

Empirical Regimens (NICE / ESC):

Native Valve, Subacute Presentation: IV Ampicillin/Amoxicillin (2 g 4-hourly) + IV Gentamicin (1 mg/kg BD) OR IV Ceftriaxone monotherapy.

Native Valve, Acute Severe Sepsis / MRSA Risk: IV Vancomycin (15–20 mg/kg BD with trough monitoring) + IV Gentamicin.

Prosthetic Valve Endocarditis (PVE): IV Vancomycin + IV Gentamicin + Oral Rifampicin (penetrates biofilms on foreign material; started 3–5 days after vancomycin to avoid rapid emergence of resistance).

Indications for Urgent Cardiac Surgery in IE:

Heart Failure: Severe acute aortic or mitral regurgitation causing pulmonary oedema or cardiogenic shock (leading surgical indication).

Uncontrolled Infection: Perivalvular extension (aortic root abscess manifested on ECG by a new prolonged PR interval / first-degree heart block ), persistent fever and positive cultures >7–10 days despite appropriate bactericidal therapy, or infection with resistant organisms (fungi, MDR Gram-negatives).

Prevention of Embolism: Large mobile vegetations (>10 mm) following one or more systemic embolic episodes, or very large isolated vegetations (>15 mm).

Antimicrobial Therapy

Treatment is prolonged, intravenous and organism-directed, and the duration depends on whether the valve is native or prosthetic.

  • Situation Typical UK empirical regimen
  • Native valve, indolent presentation Amoxicillin (with or without gentamicin)

Native valve, severe sepsis or suspected Staphylococcus aureus Flucloxacillin, or vancomycin if MRSA risk or penicillin allergy

Prosthetic valve Vancomycin plus gentamicin plus rifampicin

Native valve infection is usually treated for 4-6 weeks ; prosthetic valve endocarditis requires at least 6 weeks , with rifampicin added for its activity against organisms in biofilm. Rifampicin is not started until bacteraemia is clearing, and it is a potent CYP450 inducer that will destabilise warfarin.

Culture-Negative Endocarditis

Around 5-10% of cases are blood-culture negative, most often because antibiotics were given before cultures were taken — the single commonest and most avoidable cause. Genuine fastidious organisms to consider are Coxiella burnetii (Q fever, in farmers and abattoir workers), Bartonella species (homelessness, body lice, cat exposure), Brucella , Tropheryma whipplei and the HACEK group, which now usually do grow in modern automated systems. Serology and 16S ribosomal RNA PCR on excised valve tissue are the diagnostic routes.

Non-Infective and Special Situations

Non-bacterial thrombotic (marantic) endocarditis produces sterile vegetations in advanced malignancy, especially adenocarcinoma, and presents with embolic stroke rather than fever. Libman-Sacks endocarditis occurs in systemic lupus erythematosus and antiphospholipid syndrome. Right-sided endocarditis, typically tricuspid Staphylococcus aureus disease in people who inject drugs, causes septic pulmonary emboli with multiple cavitating nodules on chest imaging rather than systemic embolism, and murmurs are frequently absent.

Prophylaxis: the UK Position

UK practice diverges from some international guidance and is examined for exactly that reason. NICE does not recommend routine antibiotic prophylaxis against infective endocarditis for people undergoing dental or other interventional procedures. Emphasis is instead placed on maintaining good oral health, on advising at-risk patients about the symptoms of endocarditis and the need to seek early advice, and on investigating unexplained fever in patients with prosthetic valves or previous endocarditis promptly with three sets of blood cultures from separate sites before antibiotics .